AUGMENTATION OF ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY FOLLOWING INVIVO THERAPY WITH RECOMBINANT INTERLEUKIN-2
- 1 September 1990
- journal article
- research article
- Vol. 50 (17) , 5234-5239
Abstract
Monoclonal antibodies (mAB) with tumor specificity are able to enhance the immunological specificity of interleukin 2 (IL-w)-activated lymphokine activated killer (LAK) cells. Antibodies may also be used to broaden the range of tumor types susceptible to immune mediated cytotoxicity by the activated LAK cells. In these studies, mAB with relative tumor specificity were used to target immunologically activated effector cells in an in vitro antibody dependent cell mediated cytotoxicity (ADCC) assay. The mAB included: 3F8 and 14.G2a, which are both specific for neuroblastoma and melanoma and recognize ganglioside GD2, and mAB ING-1, a mouse-human chimeric antibody with constant regions from human IgG1 and kappa chains and variable regions from a mouse mAB that binds to a broad range of human adenocarcinomas. Each of these mAB was able to mediate ADCC with fresh effector cells and antibody binding targets. When peripheral blood mononuclear cells were obtained from cancer patients prior to and following in vivo therapy with interleukin 2, a significant increase was noted in ADCC activity by peripheral blood mononuclear cells obtained following IL-2 therapy. Inclusion of IL-2 in the medium during the cytotoxic assay with mAB further boosted ADCC. The total activity seen was often greater than the sum of the independent LAK activity and standard ADCC activity. The cells responsible for this ADCC had the CD16+ Fc receptor. Combining IL-2 with mAB in clinical tumor therapy may lead to wider range of tumor types being responsive to immunotherapy and may also enhance the efficacy of therapy by specifically targeting activated effector cells to tumor cells recognized by mAB. Our results provide strong support for the testing of these hypotheses in clinical trials by combining in vivo treatment with IL-2 and mAB able to mediate ADCC.This publication has 33 references indexed in Scilit:
- Lymphokine-activated killer cells. Analysis of progenitors and effectors.The Journal of Experimental Medicine, 1986
- Radioimmunodetection of Cutaneous T-Cell Lymphoma with111In-Labeled T101 Monoclonal AntibodyNew England Journal of Medicine, 1986
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.The Journal of Immunology, 1986
- Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.Proceedings of the National Academy of Sciences, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- The standardization of NK cell assays for use in studies of biological response modifiersJournal of Immunological Methods, 1984
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of Experimental Medicine, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- INVITRO GROWTH OF CYTO-TOXIC HUMAN-LYMPHOCYTES .4. LYSIS OF FRESH AND CULTURED AUTOLOGOUS TUMOR BY HUMAN-LYMPHOCYTES CULTURED IN T-CELL GROWTH-FACTOR1981